Mustang Bio Stock Price, News & Analysis

Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.

Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers, and its news flow reflects both scientific progress and capital markets activity. The company focuses on CAR T-cell therapies and an HSV-1 oncolytic virus, with programs aimed at malignant glioma, recurrent glioblastoma (GBM), high-grade astrocytomas, and related brain tumors.

News about Mustang Bio often centers on pipeline milestones, including updates on MB-101, an IL13Rα2-targeted CAR T-cell therapy, and MB-108, an HSV-1 oncolytic virus. The company has reported U.S. Food and Drug Administration Orphan Drug Designations for MB-108 in malignant glioma and MB-101 in recurrent diffuse and anaplastic astrocytoma and glioblastoma. Mustang Bio also highlights the MB-109 regimen, which combines MB-101 and MB-108 to reshape the tumor microenvironment and potentially enhance CAR-T activity in recurrent GBM and high-grade astrocytomas.

Investors following MBIO news will also see listing and financing developments, such as reverse stock split announcements, Nasdaq compliance updates on minimum bid price and stockholders’ equity requirements, and details of public offerings and warrant exercises. These items provide context on Mustang Bio’s access to capital and its efforts to maintain its Nasdaq Capital Market listing.

This news page aggregates Mustang Bio’s press releases and related coverage, giving readers a single place to review regulatory designations, clinical trial updates, facility and operational changes, and securities offerings. For those tracking MBIO, revisiting this page can help monitor how Mustang Bio’s cell therapy programs and corporate actions evolve over time.